Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment ...

Information on the disease and treatments, assistance with insurance, and transportation are among the types of support ...

Among patients who became MRD negative at a 10-5 sensitivity, 38.6% in the D-VRd arm had sustained MRD negativity vs 17.4% in the control arm (P = .0006). At the 10 -6 sensitivity, these ...

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...

A key FDA committee recently voted to allow MRD as an early regulatory endpoint in multiple myeloma, based in part on our analysis. They will hear about different types of antibodies for CD38 ...

A Darzalex-based regiment improved MRD negativity rates while sustaining MRD negativity compared with VRd in patients with ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a biotech company developing the industry’s leading ...

Based on my last bone marrow biopsy in June 2023, I am grateful to be in complete remission. In the world of multiple myeloma, minimal residual disease (MRD; amount of cancer that remains in the body) ...

Residual disease can now be tracked in hematological malignancies, including leukemia, lymphoma and myeloma, and the benefits of these MRD tests have grown in tandem with their sensitivity and ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...

Telo's MRD clinical trials with McGill University have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include ...